

March 2021 PDL/DUR Board Meeting Minutes

Date: March 24, 2021

Members Present: King, Anglim, Caldwell, Maxwell, McGrane, Nauts, Stone, Blake, Jost (arrived 1:05), Brown (arrived 2:00)

Members Absent: Blank, Putsch

Others Present: Shannon Sexauer, Dani Feist, Dan Peterson (DPHHS); Artis, Bahny, Barnhill, Doppler, Opitz, Woodmansey (MPQHF); Kathy Novak (Magellan); and representatives from the pharmaceutical industry.

Introductions: Tony King opened the meeting.

Meeting Minute Review: The meeting minutes from February 3, 2021 DUR were approved as written.

Public Comment: The public had an opportunity to address the committee regarding non-agenda items and make other social comments. No comments made.

Department Update: The State Senate approved Adam Meier as the new Director of the Department of Public Health and Human Services.

PREFERRED DRUG LIST MEETING

Prior to the discussion of the categories, the Board noted their preference to have biosimilar medications treated similarly to generic medications. This would mean that any new biosimilar medication would not trigger a review of the class of medications in a red category for a new medication. Any new biosimilar would be mentioned during the discussion of that class independent of the category in which it was classified.

Results of the Board review of Group 3 (Red category):

CLASS	DRUGS Reviewed	2021 RECOMMENDATIONS	Grandfather
COLONY STIMULATING FACTORS	ND-Nyvepria®	Therapeutic alternatives.	NO
GROWTH HORMONE	ND-Sogroya®	Therapeutic alternatives. <i>*Sogroya® not being discussed at this time as it is currently not available on the market.</i>	NO
HAE TREATMENT	ND-Orladeyo® NI-Haegarda®	Therapeutic alternatives. Must include one on-demand treatment and one prophylactic treatment. Continue with existing PA criteria.	NO

CLASS	DRUGS Reviewed	2021 RECOMMENDATIONS	Grandfather
HYPOGLYCEMICS, SGLT2	NI-Farxiga®	Must have one agent with cardiovascular disease benefit. All others class effect. Continue existing PA criteria for class.	NO
LIPOTROPICS, OTHER	ND-Nexlizet® ND-Nexletol®	Must have gemfibrozil and one fenofibrate. May add others.	NO
PLATELET AGGREGATION INHIBITORS	NI-Brilinta®	Must have immediate release aspirin. Must have one of prasugrel, clopidogrel, ticagrelor, or vorapaxar. Class effect for other agents. Grandfathered.	YES
POTASSIUM BINDERS	Class review – not drug specific	Therapeutic alternatives.	NO
PROTON PUMP INHIBITORS/H. PYLORI AGENTS	ND-Talicia®	Class effect.	NO

The Board reviewed the blue category in advance of the meeting- Kathy from Magellan reported on new doses and discontinued items in this category. This category of drugs has no new clinically significant information since last review. Board recommendations for Group 2 (Blue category) from 2020 were retained. They are as follows:

CLASS	2021 RECOMMENDATIONS	Grandfather
ANDROGENIC AGENTS, TOPICAL	Class effect.	NO
ANGIOTENSIN MODULATORS & COMBO	<u>Angiotensin Modulator Combinations:</u> Therapeutic alternatives. <u>Angiotensin II Receptor Blockers & Combinations:</u> Therapeutic alternatives. <i>*Updated American College of Cardiology (ACC) guidelines were presented. The new indication for Entresto® will be reviewed in 2022 as it did not meet the cutoff date for new information for this meeting.</i> <u>ACE Inhibitors & Combinations:</u> Class effect. Do Not Add Tekturna® or Tekturna HCT® (due to aliskiren).	NO
ANTICOAGULANTS	Must have one LMWH, warfarin, Eliquis®, and Xarelto®. May add others.	NO
ANTIEMETICS	Must have one 5-HT3 agent and one metoclopramide product. May add others. Continue with existing PA criteria.	NO
ANTIHYPERURICEMICS	Must have allopurinol and a single ingredient colchicine product. May add others. Continue with existing PA criteria.	NO

CLASS	2021 RECOMMENDATIONS	Grandfather
ANTI-ANGINAL/ANTI-ISCHEMIC AGENTS	May add with PA criteria.	NO
BETA-BLOCKERS	Must have metoprolol ER and carvedilol in some form. All other single ingredient agents have a class effect. Do not add combo agents containing diuretics-not first line agents and issues of concern with thiazides.	NO
BILE SALTS	Must have one ursodiol.	NO
BONE RESORPTION SUPPRESSION & RELATED AGENTS	<u>Nasal Calcitonins</u> : Class effect with existing PA criteria. <u>Bisphosphonates & Bone Resorption. Others</u> : Class effect.	NO
CALCIUM CHANNEL BLOCKERS (DHP & non-DHP) and COMBOS	Must have a long-acting diltiazem and a long-acting verapamil. Must have amlodipine. All others are class effect.	NO
ERYTHROPOIESIS STIMULATING AGENTS-HEMATOPOIETIC AGENTS	Therapeutic alternatives.	NO
ESTROGEN: ORAL & TRANSDERMAL	Class effect. Must have one topical and one oral.	NO
VAGINAL ESTROGEN AND OTHERS	Therapeutic alternatives	NO
GI MOTILITY, CHRONIC	Therapeutic alternatives for each of the following categories: OIC: Movantik, Relistor, Amitiza, Symproic IBS-D: Alosetron, Viberzi IBS-C/CIC: Amitiza, Linzess, Trulance, Motegrity Continue with existing PA Criteria.	NO
GLUCAGON AGENTS	Therapeutic alternatives.	NO
HYPOGLYCEMICS: ALPHA GLUCOSIDASE INHIBITORS	Class effect.	NO
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	<u>DPP-IV Inhibitors</u> : Therapeutic alternatives. Must have one single ingredient agent. <u>GLP-1 & Combinations</u> : Therapeutic alternatives, must have one single ingredient agent, must have one agent with CV benefit.	NO
HYPOGLYCEMICS, INSULINS	Class effect for each group. Must have one from each. (Human R, N, Rapid-acting, Long-Acting, Rapid/Intermediate, Reg/Intermediate Combos). Must have U-500 pen, do not add U-500 vial.	NO
HYPOGLYCEMICS: MEGLITINIDES	Class effect.	NO
HYPOGLYCEMICS: METFORMINS	Must have metformin IR. Class effect for others.	NO
HYPOGLYCEMICS: SULFONYLUREAS	Class effect.	NO
HYPOGLYCEMICS: TZDs	Class effect. Continue with existing PA criteria.	NO

LIPOTROPICS: STATINS & COMBOS	Must have 1 high potency agent. May add others.	NO
PAH AGENTS: ORAL AND INHALED	Must have one ERA and one PDE-5. May add others. Retain GF & existing PA criteria.	YES
PANCREATIC ENZYMES	Class effect with patients being grandfathered on current treatment.	YES
PHOSPHATE BINDERS	Class effect.	NO
PROGESTINS FOR CACHEXIA	Class effect.	NO
ULCERATIVE COLITIS AGENTS	Class effect. Must have more than one route.	NO

Two green categories were not reviewed as all chemical entities are preferred at this time.

Class
IDIOPATHIC PULMONARY FIBROSIS
UTERINE DISORDER TREATMENTS

Meeting adjourned at 2:12pm

Next meeting will be April 21, 2021. It is currently set for the same format. Additional information will be posted by the Department.